Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto

a technology which is applied in the field of aryl and heteroaryl derivatives, can solve the problems of elevated blood glucose levels, serious health problems, and inability to move glucose into the cells of the individual, and achieve the effect of reducing the weight gain of the individual

Inactive Publication Date: 2007-03-29
ARENA PHARMA
View PDF11 Cites 54 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention is about certain compounds that can bind to and modify the activity of a protein called RUP3. These compounds can be used for screening and testing the activity of RUP3. The invention also includes certain fused aryl and heteroaryl derivatives that can bind to RUP3. The compounds can be used for treating diseases that are influenced by RUP3. The invention also includes certain nucleotide sequences and amino acid sequences that make up RUP3. The invention provides methods for making and using these compounds.

Problems solved by technology

However, people who have diabetes either don't produce insulin or can't efficiently use the insulin they produce; therefore, they can't move glucose into their cells.
Glucose accumulates in the blood creating a condition called hyperglycemia, and over time, can cause serious health problems.
NIDDM is characterized by a relative disparity between endogenous insulin production and insulin requirements, leading to elevated blood glucose levels.
In addition, the onset can be insidious or even clinically inapparent, making diagnosis difficult.
However, after several decades, β cell function deteriorates and non-insulin-dependent diabetes develops in about 20% of the obese population (Pederson, P. Diab. Metab. Rev.
However, the factors which predispose a fraction of patients to alteration of insulin secretion in response to fat accumulation remain unknown.
There are problems with this definition in that it does not take into account the proportion of body mass that is muscle in relation to fat (adipose tissue).
As the BMI increases there is an increased risk of death from a variety of causes that is independent of other risk factors.
Orlistat (a lipase inhibitor) inhibits fat absorption directly and tends to produce a high incidence of unpleasant (though relatively harmless) side-effects such as diarrhea.
However, both products were withdrawn after reports of preliminary evidence of heart valve abnormalities associated with their use.
Obesity considerably increases the risk of developing cardiovascular diseases as well.
Kidney disease, also called nephropathy, occurs when the kidney's “filter mechanism” is damaged and protein leaks into urine in excessive amounts and eventually the kidney fails.
Diabetes is also a leading cause of damage to the retina at the back of the eye and increases risk of cataracts and glaucoma.
Finally, diabetes is associated with nerve damage, especially in the legs and feet, which interferes with the ability to sense pain and contributes to serious infections.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
  • Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
  • Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto

Examples

Experimental program
Comparison scheme
Effect test

example 1

96—well Cyclic AMP Membrane Assay for RUP3

Materials:

[0631] 1) Adenlyl cyclase Activation Flashplate Assay kit from Perkin Elmer—96 wells (SMP004B) and 125I tracer (NEX130) which comes with the kit. Keep in refrigerator, in a box, and do not expose the Flashplates to light. [0632] 2) Phosphocreatine—Sigma P-7936 [0633] 3) Creatine Phosphokinase—Sigma C-3755 [0634] 4) GTP—Sigma G-8877 [0635] 5) ATP—Sigma A-2383 [0636] 6) IBMX—Sigma 1-7018 [0637] 7) Hepes—1M solution in distilled water—Gibco #15630080 [0638] 8) MgCl2—Sigma M—1028—1M Solution [0639] 9) NaCl—Sigma—S6546—5M Solution [0640] 10) Bradford Protein Assay Kit—Biorad # 5000001 [0641] 11) Proclin 300—Sigma #4-8126

Binding Buffer—filter through 45-micron Nalgene filter and keep in refrigerator. All buffers and membranes should be kept cold (in ice bucket) while performing assay. [0642] 20 mM Hepes, pH7.4 [0643] 1 mM MgCl2 [0644] 100 mM NaCl [0645] 2× Regeneration Buffer (make in binding buffer): [0646] 20 mM Phosphocreatine (1...

example 2

A. RT-PCR Analysis of RUP3 Expression in Human Tissues (FIG. 1A).

[0690] RT-PCR was applied to determine the tissue distribution of RUP3. Oligonucleotides used for PCR had the following sequences:

ZC47:(forward primer),5′-CATTGCCGGGCTGTGGTTAGTGTC-3′;(SEQ ID NO:3)ZC48:(reverse primer),5′-GGCATAGATGAGTGGGTTGAGCAG-3′;(SEQ ID NO:4)

[0691] and the human multiple tissue cDNA panels (MTC, Clontech) were used as templates (1 ng cDNA per PCR amplification). Twenty-two (22) human tissues were analyzed. PCR was performed using Platinum PCR SuperMix (Life Technologies, Inc.; manufacture instructions were followed) in a 50 μl reaction by the following sequences: step 1, 95° C. for 4 min; step 2, 95° C. for 1 min; step 3, 60° C. for 30 sec; step 4, 72° C. for 1 min; and step 5, 72° C. for 7 min. Steps 2 through 4 were repeated 35 times.

[0692] The resulting PCR reactions (15 μl) were loaded on a 1.5% agarose gel to analyze the RT-PCR products, and a specific 466 base-pair DNA fragment representi...

example 3

RUP3 Protein Expression is Restricted to β Cell Lineage of Pancreatic Islets (FIG. 2)

[0697] A. A Polyclonal Anti-RUP3 Antibody was Prepared in Rabbits (FIG. 2A).

[0698] Rabbits were immunized with an antigenic peptide with sequence derived from rat RUP3 (“rRUP3”). The peptide sequence was RGPERTRESAYHIVTISHPELDG and shared 100% identity with mouse RUP3 in the corresponding region. A cysteine residue was incorporated at the N-terminal end of this antigenic peptide to facilitate KLH crosslinking before injecting into rabbits. The resulting antisera (“anti-rRUP3”) and the corresponding preimmune sera (“pre-rRUP3”) were tested for immune reactivity to mouse RUP3 in immunobloting assays (lanes 1 though 4). In this assay, the GST-RUP3 fusion protein was readily recognized by the anti-rRUP3 antisera (lane 4), but not by the preimmune sera (lane 2). The immunoreactive signal could be efficiently eliminated when the immunobloting assay was performed in the presence of excess antigenic pepti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to certain fused aryl and heteroaryl derivatives of Formula (I) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the prophylaxis or treatment of metabolic disorders and complications thereof, such as, diabetes and obesity.

Description

CROSS REFERENCE TO RELATED APPLICATIONS [0001] This application is a continuation of U.S. Ser. No. 11 / 355,785, filed Feb. 16, 2006, which is a divisional of U.S. Ser. No. 10 / 890,549, now U.S. Pat. No. 7,132,426, filed Jul. 13,2004, which in turn claims the benefit of U.S. Provisional Applications Ser. Nos. 60 / 487,443, filed Jul. 14, 2003 and 60 / 510,644, filed Oct. 10, 2003, each of which is hereby incorporated by reference in its entirety.FIELD OF THE INVENTION [0002] The present invention relates to certain fused aryl and heteroaryl derivatives that are modulators of glucose metabolism. Accordingly, compounds of the present invention are useful in the prophylaxis or treatment of metabolic disorders and complications thereof, such as, diabetes and obesity. BACKGROUND OF THE INVENTION [0003] Diabetes mellitus is a serious disease afflicting over 100 million people worldwide. In the United States, there are more than 12 million diabetics, with 600,000 new cases diagnosed each year. [0...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/551A61K31/519C07D487/02A61P3/00A61P3/10C07D215/22C07D215/233C07D471/04C07D473/00C07D487/04C07D498/04
CPCC07D215/233C07D471/04C07D473/00C07D487/04A61P3/00A61P3/04A61P3/06A61P3/08A61P43/00A61P5/50A61P3/10C07D498/04
Inventor JONES, ROBERTSEMPLE, GRAEMEXIONG, YIFENGSHIN, YOUNG-JUNREN, ALBERTCALDERON, IMELDAFIORAVANTI, BEATRIZCHOI, JINSAGE, CARLETON
Owner ARENA PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com